leadf
logo-loader
viewFrontier IP Group PLC

Frontier IP ticks up as Exscientia signs collaboration deal with Chinese biotech firm

As part of the partnership, Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programmes

Drugs
GT Apeiron was launched by private equity firm GT Healthcare, which is also an Exscientia investor

Frontier IP Group PLC’s (LON:FIPP) shares ticked up on Friday after its portfolio firm Exscientia entered a drug discovery collaboration with Shanghai-based biotech firm GT Apeiron Therapeutics.

The AIM-listed firm, which commercialises intellectual property, said as part of the partnership Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programmes.

READ: Frontier IP’s Fieldwork Robotics sees success in initial trials of fruit-picking robot

GT Apeiron was launched by GT Healthcare Capital Partners (GTH), a life science-focused private equity partnership, with US$27mln of financial backing.

GTH is also an investor in Exscientia having participated in a US$26mln funding round previously.

Professor Andrew Hopkins, Exscientia's chief executive, said medicines generated by the collaboration would focus on areas of “significant unmet need with global potential”.

"This is an exciting time for pharmaceutical research, with innovative approaches to drug discovery as well as the development of new commercial markets. Both are strongly evident in China, already the second largest national pharmaceutical market in the world, where we are delighted to join our expertise and technology with GT Apeiron to initiate our first discovery opportunity in the country”, the CEO added.

Frontier holds a 3.32% stake in Exscientia.

The shares were up 0.6% at 79p in early deals.

--Adds share price--

Quick facts: Frontier IP Group PLC

Price: 70 GBX

AIM:FIPP
Market: AIM
Market Cap: £38.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Frontier IP Group teams up with University of Cambridge to tackle gum disease

Frontier IP Group PLC's (LON:FIPP) Neil Crabb discusses with Proactive London's Andrew Scott a new joint project between themselves and the University of Cambridge to tackle gum disease. The study's received a £52,891 grant from the National Biofilms Innovation Centre (NBIC). The...

on 19/6/20

2 min read